|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The expanded role of fatty acid metabolism in cancer:new aspects and targets显示文摘Cancer cells undergo metabolic reprogramming to support cell proliferation,growth,and dissemination.Alterations in lipid metabolism,and specifically the uptake and synthesis of fatty acids(FAs),comprise onewelldocumented aspect of this reprogramming.Recent studies have revealed an expanded range of roles played by FA in promoting the aggressiveness of cancer while simultaneously identifying new potential targets for cancer therapy.This article provides a brief review of these advances in our understanding of FA metabolism in cancer,highlighting both recent discoveries and the inherent challenges caused by the metabolic plasticity of cancer cells in targeting lipid metabolism for cancer therapy. | Ming Chen Jiaoti Huang | 2019 | Precision Clinical Medicine2019，2，3： | 6 |
| 2 | Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation显示文摘大多数前列腺癌症(PCas ) 作为 acinar 类型被分类(常规) 有包括雄激素受体(AR ) 和前列腺特定的抗原(PSA ) 的表示的钠区别的肿瘤房间镇静的腺癌。在腺癌的每种情况中有也散布的 neuroendocrine (NE ) 房间。NE 房间是 quiesecent,不表示 AR 或 PSA,并且他们的功能仍然保持不清楚。我们证明了那条 IL8-CXCR2-P53 小径提供一个生长禁止的信号并且把 NE 房间放在良性的前列腺和腺癌静止。有趣地,在神经质的治疗,和如此的肿瘤由是的纯 NE 房间组成以后,有腺癌的历史的一些病人与小房间 neuroendocrine 癌(SCNC ) 复发高度 proliferative 并且好攻击,由于 P53 变化和 IL8-CXCR2-P53 小径的 inactivation。SCNC 的发生将多半由于进一步禁止 AR 功能或 intratumoral 雄激素合成的新奇的药的普遍使用增加。阶段 II 试用证明了基于铂的化疗可能为如此的导致治疗的肿瘤是有用的。 | Julia Lipianskaya Alexa Cohen Clark J Chen Elaine Hsia Jill Squires Zhen Li Yaqun Zhang Wei Li Xufeng Chen Hua Xu Jiaoti Huang | 2014 | Asian Journal of Andrology2014，16，4： | 6 |
| 3 | Neuroendocrine differentiation of prostate cancer显示文摘 | Zhen Li Clark J Chen Jason K Wang Elaine Hsia Wei Li Jill Squires Yin Sun Jiaoti Huang | 2013 | Asian Journal of Andrology2013，15，3： | 5 |
| 4 | Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression显示文摘Prostate cancer is among the most common malignancies in Western countries, and its incidence is rapidly rising in Asia where it was traditionally considered an uncommon tumor. Our understanding of the disease and management strategies continue to evolve. The first revolution of its treatment was in the 1940s when hormonal therapy was used to treat patients. | Ninghan Feng Jiaoti Huang | 2019 | Asian Journal of Andrology2019，21，3： | 5 |
| 5 | The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in cancer patients显示文摘Circulating cell-free DNAs(cfDNAs)are fragmented DNA molecules released into the blood by cells.Previous studies have suggested that mitochondria-originated cfDNA fragments(mt-cfDNAs)in cancer patients are more fragmented than those from healthy controls.However,it is still unknown where these short mtcfDNAs originate,and whether the length of mt-cfDNAs can be correlated with tumor burden and cancer progression.In this study,we first performed whole-genome sequencing analysis(WGS)of cfDNAs from a human tumor cell line-xenotransplantation mouse model and found that mt-cfDNAs released from transplanted tumor cells were shorter than the mouse counterpart.We next analyzed blood cfDNA samples from hepatocellular carcinoma and prostate cancer patients and found that mt-cfDNA lengths were inversely related to tumor size as well as the concentration of circulating tumor DNA.Our study suggested that monitoring the size of mt-cfDNAs in cancer patients would be a useful way to estimate tumor burden and cancer progression. | Qin An Youjin Hu Qingjiao Li Xufeng Chen Jiaoti Huang Matteo Pellegrini Xianghong Jasmine Zhou Matthew Rettig Guoping Fan | 2019 | Precision Clinical Medicine2019，2，3： | 4 |
| 6 | Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer显示文摘前列腺癌症是在人的第二很普通的癌症,与一最近的年里的世界健康组织全球报导的 110 万个新案例。指导活体检视被用于的 Transrectal 超声(TRUS ) 为超过 2 十年的前列腺癌症的诊断,而是这种技术对癌症通常盲目地点。而且, TRUS 活体检视的假否定的率被报导了象 47% 一样高。Multiparametric 磁性的回声成像(mp-MRI ) 包括 T1 加权、 T2 加权的成像象一样动态提高对比(数据通信设备) 并且散开加权的成像(DWI ) 。mp-MRI 是在前列腺癌症的成像的主要进展,启用可疑损害的指向的活体检视。演变指向的活体检视 techniques—包括的直接在里面厌烦活体检视,认知熔化和基于软件的 MRI 超声(MRI 美国) fusion—与更早的方法相比在癌症察觉导致了好几倍的改进。重要地,临床上重要的癌症的察觉被指向极大地便于,与系统的活体检视相比独自一个。经由 MRI 美国熔化的指向的活体检视可以戏剧性地改变前列腺癌症被诊断并且设法的方法。 | Jesse D Le Jiaoti Huang Leonard S Marks | 2014 | Asian Journal of Andrology2014，16，4： | 3 |
| 7 | Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration-Resistant Prostate Cancer显示文摘 | Shancheng Ren Yawei Liu Weidong Xu Yi Sun Ji Lu Fubo Wang Min Wei Jian Shen Jianguo Hou Xu Gao Chuanliang Xu Jiaoti Huang Yi Zhao Yinghao Sun | 2013 | The Journal of Urology2013，，： | 2 |
| 8 | The molecular basis for ethnic variation and histological subtype differences in prostate cancer显示文摘Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity and mortality of prostate cancer increase dramatically in several oriental countries including China. Rapidly evolving technology in molecular biology such as high-throughput sequencing and integrative analysis of genomic and transcriptomic landscapes have enabled the identification of key oncogenic events for prostate cancer initiation, progression and resistance to hormonal therapy. These surging data of prostate cancer genome also provide insights on ethnic variation and the differences in histological subtype of this disease. In this review, differences in the incidence of prostate cancer and the prevalence of main genetic alterations between Asian and Western populations are discussed. We also review the recent findings on the mechanisms underlying neuroendocrine differentiation of prostate cancer and the development of small cell neuroendocrine carcinoma after androgen deprivation therapy. | ZONG Yang GOLDSTEIN Andrew S. HUANG JiaoTi | 2013 | Science China(Life Sciences)2013，56，9： | 2 |
| 9 | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer显示文摘Since androgen receptor(AR)signaling is critically required for the development of prostate cancer(PCa),targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa.Unfortunately,although the tumor initially responds to the therapy,treatment resistance eventually develops and the disease will progress.It is therefore imperative to identify the mechanisms of therapeutic resistance and novel molecular targets that are independent of AR signaling.Recent advances in pathology,molecular biology,genetics and genomics research have revealed novel AR-independent pathways that contribute to PCa carcinogenesis and progression.They include neuroendocrine differentiation,cell metabolism,DNA damage repair pathways and immune-mediated mechanisms.The development of novel agents targeting the non-AR mechanisms holds great promise to treat PCa that does not respond to AR-targeted therapies. | Lingfan Xu Junyi Chen Weipeng Liu Chaozhao Liang Hailiang Hu Jiaoti Huang | 2019 | Asian Journal of Urology2019，6，1： | 2 |
| 10 | Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma显示文摘 | Mai Gu Weiji Shi Jiaoti Huang | 2000 | Cancer Cytopathology2000，90，： | 1 |
| 11 | Fasting times in serum PSA assay显示文摘 | Xiang Xu Julia Lipianskaya Jiaoti Huang | 2014 | Asian Journal of Andrology2014，16，5： | 1 |
| 12 | Meet Guest Editor显示文摘Dr. Huang earned his medical degree from Anhui Medical University, and obtained a Master's degree in pharmacology from Beijing Institute of Radiation Medicine. He came to the US in 1987 and earned his PhD in Molecular and Cellular Biology from NYU School of Medicine in 1991. He was a Leukemia Society of America Postdoctoral Fellow at NYU and Yale University. He did his residency in Anatomic and Clinical Pathology at NYU and fellowship in Oncologic Surgical Pathology at Memorial Sloan- Kettering. He became an assistant professor at the University of Rochester in July 2000 and rose to the rank of full professor in 2007. Dr. Huang moved to UCLA in 2008 to be Professor of Pathology and later Director of Surgical Pathology. He arrived at Duke at the beginning of 2016 to be Chairman of the Department of Pathology. | Prof. Jiaoti Huang | 2019 | Asian Journal of Andrology2019，21，3： | 1 |
| 13 | CD44 expression is a feature of prostatic small cell Carcinoma and Distinguishes it from its Mimickers显示文摘 | Rochelle A. Simon P. Anthony di Sant’Agnese Li-Shan Huang Haodong Xu Jorge L. Yao Qi Yang Sharon Liang Jinsong Liu Rena Yu Liang Cheng William K. Oh Ganesh S. Palapattu Jianjun Wei Jiaoti Huang | 2009 | Human Pathology2009，，2： | 1 |
| 14 | Neuroendocrine differentiation in prostate cancer显示文摘 | Yin Sun Junyang Niu Jiaoti Huang | | 0，，02： | 1 |
| 15 | Neuroendocrine cells of the prostate:Histology,biological functions,and molecular mechanisms显示文摘Prostate cancer(PCa)is a common cause of cancer-related mortality inmen worldwide.Although most men are diagnosed with low grade,indolent tumors that are potentially curable,a significant subset develops advanced disease where hormone therapy is required to target the androgen receptor(AR).Despite its initial effect,hormone therapy eventually fails and the tumor progresses to lethal stages even through continued inhibition of AR.This review article focuses on the role of PCa cellular heterogeneity in therapy resistance and disease progression.Although AR-positive luminal-type cells represent the vast majority of PCa cells,there exists a minor component of AR-negative neuroendocrine(NE)cells that are resistant to hormonal therapy and are enriched by the treatment.In addition,it is now well accepted that a significant subset of hormonally treated tumors recur as small cell neuroendocrine carcinoma(SCNC),further highlighting the importance of targeting NE cells in addition to the more abundant luminal-type cancer cells.Although it has been long recognized that NE cells are present in PCa,their underlying function in benign prostate and molecular mechanisms contributing to PCa progression remains poorly understood.In this article,we review the morphology and function of NE cells in benign prostate and PCa as well as underlying molecular mechanisms.In addition,we review the major reported mechanisms for transformation from common adenocarcinoma histology to the highly lethal SCNC,a significant clinical challenge in the management of advanced PCa. | William Butler Jiaoti Huang | 2021 | Precision Clinical Medicine2021，4，1： | 0 |
| 16 | 核磁共振成像和神经保留技术在机器人辅助腹腔镜手术治疗高危前列腺癌患者中的应用显示文摘回顾研究机器人辅助腹腔镜手术(RARP)治疗高危前列腺癌(PCa)患者的手术效果,评估多参数核磁共振成像(MRI)在肿瘤分期、包膜外侵犯情况和分级中的预测作用,并评估神经保留技术(NS)在RARP中的应用效果。回顾2009年12月至2013年10月由同一个术者完成的高危前列腺癌患者的RARP病例,研究其一般资料、术前MRI影像资料、手术资料、病理资料、性功能恢复情况、控尿情况和手术切缘(SM)情况。44例高危前列腺癌患者接受了RARP手术,中位随访时间为24个月,切缘阳性(PSM)率为14%,控尿良好率86%,性功能恢复率58%。其中有25例术前做了多参数MRI,MRI将临床分期的准确率从28%提升到88%。在组织病理切片上研究性神经保留的程度,将其分为A组(双侧Ns)、B组(单侧NS)、C组(部分NS)和D组(无NS)。发现这四组控尿良好率分别为100%、92%、91%和50%,性功能恢复率分别为100%、80%、45%和0%。性功能恢复情况与切缘阳性率负相关;术前MRI有助于提高高危前列腺癌的肿瘤定位和临床分期的准确性;性功能的保留程度受到临床分期的影响,并需要在性功能恢复、控尿与切缘阳性之间找平衡。 | Jin-Guo Wang Jiaoti Huang Arnold I Chin | 2014 | Asian Journal of Andrology2014，16，5： | 0 |
| 17 | Novel genetic loci associated with prostate cancer in the rapanese population显示文摘 | Yin Sun Jiaoti Huang | 2011 | Asian Journal of Andrology2011，13，1： | 0 |
| 18 | The role of glutamine metabolism in castration-resistant prostate cancer显示文摘Reprogramming of metabolism is a hallmark of tumors,which has been explored for therapeutic purposes.Prostate cancer(PCa),particularly advanced and therapy-resistant PCa,displays unique metabolic properties.Targeting metabolic vulnerabilities in PCa may benefit patients who have exhausted currently available treatment options and improve clinical outcomes.Among the many nutrients,glutamine has been shown to play a central role in the metabolic reprogramming of advanced PCa.In addition to amino acid metabolism,glutamine is also widely involved in the synthesis of other macromolecules and biomasses.Targeting glutamine metabolic network by maximally inhibiting glutamine utilization in tumor cells may significantly add to treatment options for many patients.This review summarizes the metabolic landscape of PCa,with a particular focus on recent studies of how glutamine metabolism alterations affect therapeutic resistance and disease progression of PCa,and suggests novel therapeutic strategies. | Bing Zhao Jing Wang Li Chen Hong Wang Chao-Zhao Liang Jiaoti Huang Ling-Fan Xu | 2023 | Asian Journal of Andrology2023，25，2： | 0 |
| 19 | The promise of immunotherapy in genitourinary malignancies显示文摘A broad understanding of the tumor immune landscape has led to a revolution of immune checkpoint inhibitors in the treatment of multiple cancer types.In genitourinary malignancies,immune checkpoint inhibitors have improved outcomes for patients with metastatic renal cell carcinoma and metastatic urothelial carcinoma;however,these treatments have not yet proven broadly beneficial for patients with metastatic prostate cancer.Numerous prospective trials are ongoing to further improve outcomes with immunotherapy combinations and for biomarker development to predict benefit from immune checkpoint inhibition.This perspective article highlights our current immunotherapy approaches in each of the genitourinary malignancies and the ongoing clinical trials that may inform our future treatments in renal,urothelial,and prostate cancers. | Tian Zhang Andrew J.Armstrong Daniel J.George Jiaoti Huang | 2018 | Precision Clinical Medicine2018，1，3： | 0 |
| 20 | Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma显示文摘Loss of function of the von Hippel-Lindau(VHL)tumor suppressor gene is a hallmark of clear cell renal cell carcinoma(ccRCC).The importance of heterogeneity in the loss of this tumor suppressor has been under reported.To study the impact of intratumoral VHL heterogeneity observed in human ccRCC,we engineered VHL gene deletion in four RCC models,including a new primary tumor cell line derived from an aggressive metastatic case.The VHL gene-deleted(VHL-KO)cells underwent epithelial-to-mesenchymal transition(EMT)and exhibited increased motility but diminished proliferation and tumorigenicity compared to the parental VHL-expressing(VHL+)cells.Renal tumors with either VHL+or VHL-KO cells alone exhibit minimal metastatic potential.Combined tumors displayed rampant lung metastases,highlighting a novel cooperative metastatic mechanism.The poorly proliferative VHL-KO cells stimulated the proliferation,EMT,and motility of neighboring VHL+cells.Periostin(POSTN),a soluble protein overexpressed and secreted by VHL non-expressing(VHL−)cells,promoted metastasis by enhancing the motility of VHL-WT cells and facilitating tumor cell vascular escape.Genetic deletion or antibody blockade of POSTN dramatically suppressed lung metastases in our preclinical models.This work supports a new strategy to halt the progression of ccRCC by disrupting the critical metastatic crosstalk between heterogeneous cell populations within a tumor. | Junhui Hu Ping Tan Moe Ishihara Nicholas ABayley Shiruyeh Schokrpur Jeremy GReynoso Yangjun Zhang Raymond JLim Camelia Dumitras Lu Yang Steven MDubinett Parmjit SJat Jacques Van Snick Jiaoti Huang Arnold IChin Robert MPrins Thomas GGraeber Hua Xu Lily Wu | 2023 | Signal Transduction and Targeted Therapy2023，8，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员